Fate Therapeutics (FATE) Tops Q2 EPS by 13c

Fate Therapeutics (NASDAQ: FATE) reported Q2 EPS of ($0.33), $0.13 better than the analyst estimate of ($0.46). Revenue for the quarter came in at $6.77 million versus the consensus estimate of $1.33 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Trump Bought At Least $100,001 In Palantir Shares, Disclosure Shows - Bloomberg
• Nutrabolt picks banks for IPO that could raise up to $1 billion - Reuters
• SK Inc. and KKR launch $1.3B renewable energy platform in Korea